Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03597139
Other study ID # AUR-VOS-2017-01
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date August 13, 2018
Est. completion date December 13, 2018

Study information

Verified date May 2021
Source Aurinia Pharmaceuticals Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Evaluate the tolerability, efficacy and safety of VOS versus Restasis® in subjects with mild to moderate Dry Eye Disease (DED).


Description:

This is a Phase 2, multi-center, Investigator-masked, randomized, parallel-group study to evaluate the tolerability, efficacy and safety of VOS versus Restasis® over a 28-day treatment period in subjects with mild to moderate DED. Approximately 90 subjects will be randomized to either VOS or Restasis® at approximately 7 centers located in the US


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date December 13, 2018
Est. primary completion date November 9, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Have a best corrected visual acuity (BCVA) in both eyes of +0.7 logarithm of the Minimum Angle of Resolution (logMAR) or better as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) chart. 2. Have a documented history of DED in both eyes supported by a previous clinical diagnosis. 3. Have ongoing DED, as defined by at least one eye (if one eye, the same eye) meeting all the following criteria: - A symptom severity score of =30 for Eye Dryness on a Visual Analog Scale (VAS) (0-100) - An unanesthetized Schirmer Tear Test (STT) score of =1 mm and =10 mm per 5 minutes (Note: STT Score obtained at Visit 1) - Evidence of ocular surface staining (total fluorescein staining score of at least 3 [0-15 scale]). 4. Have normal lid anatomy. Exclusion Criteria: 1. Have any known hypersensitivity or contraindication to study treatments (including excipients), topical anesthetics or vital dyes. 2. Be unable to demonstrate correct instillation of over-the-counter (OTC) ocular lubricant. 3. Report discomfort in both eyes from instillation of OTC ocular lubricant during Visit 2 (based on score of =30 on the Drop Discomfort VAS). 4. Have used Restasis® (cyclosporine ophthalmic emulsion) within 30 days prior to Visit 1. 5. Have used Restasis® for more than 1 month (if prior use is reported). 6. Have used Xiidra® (lifitegrast ophthalmic solution) within 14 days prior to Visit 1. 7. Have had corneal graft surgery in either eye within 1 year. 8. Have recent or current evidence of ocular infection or inflammation in either eye. 9. Have current evidence of clinically significant blepharitis (defined as requiring lid hygiene therapy), conjunctivitis, or a history of herpes simplex or zoster keratitis in either eye.

Study Design


Intervention

Drug:
Voclosporin Ophthalmic Solution
Investigational Drug
Restasis®
Comparator

Locations

Country Name City State
United States Aurinia Investigative Center Garden Grove California
United States Aurinia Investigative Center High Point North Carolina
United States Aurinia Investigative Center Kansas City Missouri
United States Aurinia Investigative Center Memphis Tennessee
United States Aurinia Investigative Center Mission Hills California
United States Aurinia Investigative Center Rancho Cordova California
United States Aurinia Investigative Center Washington Missouri

Sponsors (1)

Lead Sponsor Collaborator
Aurinia Pharmaceuticals Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in Drop Discomfort Post Dose Instillation on Day 1 Drop Discomfort was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment 1 minute post-instillation on Day 1. The VAS scale is 0 - 100, where 0 corresponds to "no discomfort" and 100 corresponds to "maximal discomfort". 1-minute Post Dose 1 installation (Day 1)
Secondary Change From Baseline in Drop Discomfort Post Dose Instillation on Day 28 Drop Discomfort was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment 1 minute post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no discomfort" and 100 corresponds to "maximal discomfort". Day 28
Secondary Change From Baseline in Burning/Stinging Post Dose Instillation on Day 28 Burning/Stinging was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no burning/stinging" and 100 corresponds to "worst burning/stinging". Day 28
Secondary Change From Baseline in Foreign Body Sensation Post Dose Instillation on Day 28 Foreign Body Sensation was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no foreign body sensation" and 100 corresponds to "worst foreign body sensation". 28 days
Secondary Change From Baseline in Photophobia Post Dose Instillation on Day 28 Photophobia was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no photophobia" and 100 corresponds to "worst photophobia". 28 days
Secondary Change From Baseline in Eye Pain Post Dose Instillation on Day 28 Eye pain was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no eye pain" and 100 corresponds to "worst eye pain". 28 days
Secondary Change From Baseline in Eye Dryness Post Dose Instillation on Day 28 Eye dryness was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no eye dryness" and 100 corresponds to "worst eye dryness". 28 days
Secondary Change From Baseline in Itching Post Dose Instillation on Day 28 Itching was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no itching" and 100 corresponds to "worst itching". 28 days
Secondary Change From Baseline in the Total of All Individual Symptom Severity Assessment Scores The Individual Symptom Severity Assessment Visual Analog Scale (VAS) includes Burning/Stinging (scale 0 - 100; 0 = no Burning/Stinging, 100 = worst Burning/Stinging), Foreign Body Sensation (scale 0 - 100; 0 = no Foreign Body Sensation, 100 = worst Foreign Body Sensation), Photophobia (scale 0 - 100; 0 = no Photophobia, 100 = worst Photophobia), Eye Pain (scale 0 - 100; 0 = no Eye Pain, 100 = worst Eye Pain), Eye Dryness (scale 0 - 100; 0 = no Eye Dryness, 100 = worst Eye Dryness), and Itching (scale 0 - 100; 0 = no Itching, 100 = worst Itching). The total sum of all 6 symptoms (Burning/Stinging, Foreign Body Sensation, Photophobia, Eye Pain, Eye Dryness, Itching) were evaluated (scale 0 - 600; 0 = no visual symptoms, 600 = worst visual symptoms). Day 28
Secondary Change From Baseline in Symptom Assessment in Dry Eye Score (SANDE) The Symptom Assessment in Dry Eye (SANDE) is a subjective rating performed by the subjects for the frequency and severity of their dry eye symptoms. The total length of the line is 100mm. For Frequency of Symptoms 0mm = "rarely" and 100mm = "all the time". For Severity of Symptoms 0mm = "very mild" and 100mm = "very severe". Subjects were asked to subjectively rate the frequency and severity of their symptoms by placing an "X" on the relevant horizontal line. The length of the line between the "rarely" or "very mild" starting point and the first point where the subject's mark crosses each line was measured and recorded in millimeters. Day 28
Secondary Change From Baseline in Unanesthetized Schirmer Test Score The Schirmer Test Score recorded tear production on test strips. The Schirmer tear test was conducted 1 hour following administration of VOS/Comparator and 20 minutes following fluorescein corneal staining. Using a ruler and/or the millimeters recorded on the strips, a point halfway between the two lines was measured and this was recorded as the amount of wetting. Lower scores indicate less tear production and therefore a worse outcome. Normal tear production is =10mm of wetting on the test strip, and severe dry eye is <5mm of wetting on the test strip. 28 days
Secondary Change From Baseline in Fluorescein Corneal Staining (FCS) Score The FCS score was summarized for each eye separately. Each of the 5 sections of cornea (superior, inferior, nasal, temporal, central) were graded using the National Eye Institute (NEI) scale; 0, 1 (mild), 2 (moderate), or 3 (severe). The total score was obtained by summing each of the 5 sections of the cornea from 0 - 15. Lower scores indicate less staining and therefore a better outcome. 28 days
See also
  Status Clinical Trial Phase
Completed NCT06159569 - Performance and Tolerability of the Medical Device LACRIACT N/A
Completed NCT05102409 - An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease Phase 2
Completed NCT05027087 - The Effect of a Novel Blueberry Supplement on Dry Eye Disease Phase 3
Completed NCT04081610 - Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution Phase 1
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT05825599 - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms N/A
Completed NCT03418727 - Dry Eye Disease Study With Brimonidine Phase 2
Active, not recruiting NCT04425551 - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction N/A
Recruiting NCT04527887 - Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED) Phase 4
Not yet recruiting NCT06379685 - Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface. Phase 1
Active, not recruiting NCT05618730 - Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B Phase 1
Completed NCT04553432 - Dry Eye OmniLenz Application of Omnigen Research Study Phase 4
Recruiting NCT04109170 - Dry Eye Evaluation System Based on Bioinformatics
Completed NCT04105842 - Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type N/A
Completed NCT05505292 - Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers Phase 4
Completed NCT04668131 - Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease N/A
Completed NCT06176651 - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers Phase 4
Not yet recruiting NCT02218827 - Topical Steroid Treatment For Dry Eye N/A
Completed NCT02235259 - Efficacy and Safety of XG-104 for the Treatment of Dry Eye Phase 2
Completed NCT01959854 - Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye N/A